Novel bispecific human antibody platform specifically targeting a fully open spike conformation potently neutralizes multiple SARS-CoV-2 variants

A dual-targeting approach using a human bispecific antibody against the receptor-binding domain of the Middle East Respiratory Syndrome Coronavirus

“…While numerous bsAbs have been developed in the field of oncology to enhance antitumor activity, recent research focusing on bsAbs targeting the SARS-CoV-2 RBD indicates their potential effectiveness in the field of virology for enhanced virus neutralization ( De Gasparo et al, 2021 ; Yuan et al, 2022 ). In a previous study, we developed a bsAb for SARS-CoV-2, confirming its outstanding neutralizing efficacy and highlighting its potential as an efficient antibody platform ( Kim et al, 2023b ). This strategy, involving the simultaneous targeting of distinct viral antigens or epitopes using a combination of antibodies within a single bsAb, shows promise for effective virus management.…”

Overcoming antibody-resistant SARS-CoV-2 variants with bispecific antibodies constructed using non-neutralizing antibodies

“…Another approach is to investigate different antibody formats, bispecific or multispecific, that can simultaneously and synergistically bind to multiple epitopes. 42 , 43 , 44 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 …”

Overcoming antibody-resistant SARS-CoV-2 variants with bispecific antibodies constructed using non-neutralizing antibodies

“…Another approach is to investigate different antibody formats, bispecific or multispecific, that can simultaneously and synergistically bind to multiple epitopes. [42][43][44][66][67][68][69][70][71][72][73] A study on bispecific antibodies combining anti-RBD and anti-S2 antibodies has been reported. 44 The structure of these bispecific antibodies involved a combination of scFvs from neutralizing antibodies against RBD and S2, arranged in tandem in the scFv-scFv-Fc format.…”